Early and persistent human immunodeficiency virus type 1 (HIV-1)- specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 278-284

  Musey, Luwy K ^a   Krieger, John N ^b   Hughes, James P ^b   Schacker, Timothy W ^d   Corey, Lawrence ^a,c   McElrath, M Juliana ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PHYTOHEMAGGLUTININ;

ADULT; ARTICLE; CELL DESTRUCTION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL;

ADULT; CANDIDA; FEMALE; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; PHYTOHEMAGGLUTININS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TETANUS;

EID: 0033509509     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314868     Document Type: Article

References (26)

1. + T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995;172:79-87.
2. + cell numbers and clinical staging. J Clin Invest 1989;84:1892-9.
3. 3. Roos M, Miedema M, Koot M, et al. T cell function in vitro is an independent progression marker for AIDS in human immunodeficiency virus-infected asymptomatic subjects. J Infect Dis 1995;171:531-6.
4. 4. Clerici M, Hakim FT, Venzon DJ, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91:759-65.
5. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
6. 6. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS, Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985;313:79-84.
7. 7. Lederman MM, Ratnoff OD, Scillian JJ, Jones PK, Schacter B. Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med 1983; 308:79-83.
8. 8. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
9. 9. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-I infection. Nature 1995;373:123-6.
10. 10. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-64.
11. 11. Muscy L, Hughes J, Schacker T, Shea T, Corey L, McElrath M. Cytotoxic T cell responses, viral load, and disease progression in early HTV-1 infection. N Engl J Med 1997;337:1267-74.
12. 12. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification Io monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994;170:1172-9.
13. 13. Cleveland W, Grosse E, Shuy W. Local regression models. In: Statistical models. Chambers SS, Hastie T, eds. Pacific Grove, CA: Wadsworth * Brooks/Cole, 1992:309-78.
14. 14. Diggle P. Liang K, Zeger S, Analysis of longitudinal data. Oxford, UK: Oxford University Press, 1994.
15. 15. Griffin D, Ward B. Differential CD4 T cell activation in measles. J Infect Dis 1993;168:275-81.
16. 16. Holaday B, Pompeu M, Jeronimo S, et al. Potential role for interleukin-10 in the immunosuppression associated with kala-azar. J Clin Invest 1993;92: 2626-32.
17. 17. Oldstone MB. Virus-lymphoid cell interactions. Proc Natl Acad Sci USA 1996;93:12756-8.
18. 18. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I Interferon in vivo. Science 1996;272:1947-50.
19. + memory T cells. J Exp Med 1997;186: 859-65.
20. 20. Sitz KV, Loomis-Price LD, Ratto-Kim S. Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopcs in human immunodeficiency virus infected persons. J Infect Dis 1997; 176:1085-9.
21. 21. Badley AD, McElhinny JA, Leibson PJ, Lyndi DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996;70:199-206.
22. 22. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HlV)-infecled subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
23. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40,
24. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
25. + repertoire during antiviral therapy. Nat Med 1998;4:215-21.
26. 26. Pakker N, Notermans D, de Boer R, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-I infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.